Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 28, 2026, 9:41 AM ET
Genmab announced that Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab met both primary endpoints versus pembrolizumab alone, with OS HR 0.50 and ORR odds ratio 3.17 at the first interim analysis in first-line PD-L1 positive HNSCC.
$GMABBiotechnologyClinical evidenceDevelopment risk
GMAB Stock Hub: Genmab News, Antibody Therapies and Oncology
Three positive late-stage readouts sharpen the pipeline opportunity. Royalties, acquisition debt and the cost of building an owned oncology business determine the financial test.
Full research report · PDF
Genmab ($GMAB), research as of October 29, 2026
16 pages covering The archived research compares LiGeR-HN1, RAINFOL-02 and EPCORE DLBCL-2 while preserving their different populations and endpoints. It examines Genmab’s royalty base, owned-product economics, AbbVie sharing obligations, Merus acquisition funding, June cash conversion and the financial demands of an expanding oncology business. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next scheduled financial event
November 5, 2026
Publication of the interim report for the first nine months of 2026.
Full trial presentations and regulatory discussions follow separate timelines; no approval date is inferred.
GMAB stock at a glance
Close · October 30, 2026
$57.06
Regular-session close; +1.01% versus $56.49 on October 29, 2026.
Next financial disclosure
November 5, 2026
Interim report for the first nine months; separate from clinical announcements.
Cash and equivalents
$1.503B
June 30, 2026; includes $30M restricted
Total borrowings
$5.135B
June 30, 2026; current plus noncurrent
H1 revenue
$2.051B
Six months ended June 30, 2026
H1 IFRS operating profit
$555M
Six months ended June 30, 2026
H1 operating cash flow
$54M
Six months ended June 30, 2026
Petosemtamab Phase 3 OS
HR 0.50
LiGeR-HN1; October 28, 2026
Where Genmab stands now
The October 28 LiGeR-HN1 result adds randomized survival evidence for petosemtamab plus pembrolizumab. It follows positive RAINFOL-02 and EPCORE DLBCL-2 readouts in different disease settings. Existing DARZALEX royalties remain central to earnings while Genmab builds a larger owned portfolio. Detailed efficacy and safety, regulatory decisions, cash conversion and borrowing costs are the next determinants.
Positive topline results still require regulatory and commercial execution. Investigational Rina-S and petosemtamab are not approved products. Acquisition debt, development spending and partnership profit-sharing affect how clinical success may reach common shareholders.
The constructive case
Positive randomized data in petosemtamab and Rina-S broaden the potential owned portfolio, while the existing royalty business provides revenue and earnings. The next test is consistent full data, regulatory progress and productive launch spending.
The cautious case
Acquisition debt, weaker cash conversion and rising launch costs remain relevant after positive trials. Investigational medicines still require approval and commercialization, and broader sales opportunities do not guarantee attractive returns on invested capital.
Latest Genmab news
October 28, 2026
Petosemtamab meets both primary endpoints
LiGeR-HN1 reported OS HR 0.50 and ORR odds ratio 3.17 for the combination versus pembrolizumab. Regulatory discussions and full data remain ahead.
October 26, 2026
Mature Phase 2 HNSCC follow-up
The 43 efficacy-evaluable patients had median OS of 28.2 months and ORR of 63%. These are Phase 2 outcomes, separate from the newer Phase 3 topline.
October 25, 2026
Petosemtamab colorectal follow-up updated
The company reported updated follow-up analyses from its Phase 2 colorectal-cancer study. This is a separate disease setting and evidence package from the LiGeR-HN1 randomized head-and-neck trial.
October 23, 2026
Rina-S positive in RAINFOL-02
The ovarian-cancer trial met PFS and OS endpoints in the ITT and PAS analyses. The ITT PFS HR was 0.29; Rina-S remains investigational.
October 13, 2026
Third-quarter DARZALEX net sales disclosed
Genmab announced partner-reported third-quarter DARZALEX sales. Partner product sales are distinct from Genmab’s royalty revenue and cash receipts.
October 5, 2026
Epcoritamab plus R-CHOP positive
EPCORE DLBCL-2 reported PFS HR 0.49 in both the primary IPI 3–5 and broader IPI 2–5 groups, with distinct confidence intervals.
GMAB stock catalysts: development and reporting dates
- November 5, 2026 — First-nine-months interim report. Company financial calendar
- No announced approval day — Rina-S and petosemtamab regulatory discussions. Development and regulatory process
Genmab late-stage evidence: separate trials and populations
On October 28, 2026, Genmab announced that the Phase 3 LiGeR-HN1 trial met its dual primary endpoints of overall survival and objective response rate at the first interim analysis. The study compares petosemtamab plus pembrolizumab with pembrolizumab alone in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma. It is randomized, open-label, global and multicenter, with patients assigned one-to-one to the combination or control arm.
Rinatabart sesutecan, also called Rina-S or GEN1184, is an investigational folate receptor alpha-targeted antibody-drug conjugate. Its components include a human monoclonal antibody, a protease-cleavable linker and exatecan, a topoisomerase I inhibitor payload. The drug is being developed across ovarian, endometrial and other cancers, but the October 23, 2026 pivotal result concerns platinum-resistant ovarian cancer in RAINFOL-02.
GMAB royalties, acquisition debt and cash conversion
Cash and cash equivalents were $1.503 billion at June 30, 2026, compared with $1.715 billion at December 31, 2025. The June balance included $30 million of restricted cash held in escrow in connection with ProfoundBio. Cash reported on the balance sheet and cash freely deployable for operating decisions are therefore not perfectly identical. The company generated $54 million of operating cash flow in the first half of 2026, down from $349 million a year earlier. The cash-flow statement shows $317 million before financial items, followed by interest received, lease interest, $191 million of interest paid and $96 million of corporate taxes paid. Receivable growth and a reduction in other payables also absorbed cash. Positive operating profit did not translate into an equally large increase in cash.
Merlintrader Health Score · $GMAB
3.70out of 5
Assessed October 28, 2026. Weighted calculation: 3.0×30% + 4.5×30% + 3.5×20% + 4.0×10% + 3.5×10% = 3.70. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Investigational Rina-S and petosemtamab are not approved products. Acquisition debt, development spending and partnership profit-sharing affect how clinical success may reach common shareholders.
- Acquisition debt, weaker cash conversion and rising launch costs remain relevant after positive trials. Investigational medicines still require approval and commercialization, and broader sales opportunities do not guarantee attractive returns on invested capital.
GMAB Stock FAQ: Genmab Questions Answered
What changed in the October 28 petosemtamab announcement?
LiGeR-HN1 met both primary endpoints at its first interim analysis: overall survival and objective response rate. The overall-survival hazard ratio was 0.50, with a 95% confidence interval of 0.37–0.67, for petosemtamab plus pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC. Petosemtamab remained investigational.
Is Rina-S already approved after RAINFOL-02?
No. The October 23 announcement described a positive Phase 3 result and plans for regulatory discussions. Rina-S remained investigational. An approval requires a separate regulatory decision on the complete application and proposed indication.
Are the RAINFOL-02 ITT and PAS results from different trials?
No. The ITT population contained 584 randomized patients; the 492-patient PAS was a defined subset incorporating folate receptor alpha expression and prior mirvetuximab criteria. PFS hazard ratios were 0.29 in the ITT population and 0.33 in the PAS; overall-survival hazard ratios were 0.43 and 0.44 respectively.
Does Genmab receive all EPKINLY/TEPKINLY global sales?
No. First-half 2026 global sales were $312 million, but Genmab recorded $242 million of EPKINLY product sales in the United States and Japan. Sales in other territories contribute under royalty arrangements, while the company also has profit-sharing obligations to AbbVie.
How much cash and borrowing did Genmab report?
At June 30, 2026, cash and cash equivalents were $1.503 billion, including $30 million held in escrow. Borrowings totaled $5.135 billion, combining current and noncurrent amounts. These figures describe that balance-sheet date, not a live cash balance.
Primary sources
- October 28, 2026 · Petosemtamab meets both primary endpoints
- October 26, 2026 · Mature Phase 2 HNSCC follow-up
- October 25, 2026 · Petosemtamab colorectal follow-up updated
- October 23, 2026 · Rina-S positive in RAINFOL-02
- October 13, 2026 · Third-quarter DARZALEX net sales disclosed
- October 5, 2026 · Epcoritamab plus R-CHOP positive
- Financial calendar
This blog content is provided for informational and educational purposes only. It is not investment advice.
Disclaimer. Merlintrader publishes educational and informational content, not investment advice or a recommendation to buy, sell or hold securities. Analysis and scenarios are editorial interpretations, not guarantees. Research uses artificial intelligence with editorial supervision and may contain errors. Readers should verify material information and consult a licensed financial adviser where appropriate.
Biotechnology investments involve clinical, regulatory, manufacturing, intellectual-property, reimbursement and financing risks. Positive trials do not guarantee approval, a broad label or profitable commercialization. Borrowing, compensation awards or future equity issuance can affect shareholder returns. Investors may lose part or all of their capital.
Financial and clinical figures carry their own dates and can become outdated. Some links are affiliate links and may generate a commission at no additional cost to the reader. See the full disclaimer and terms and privacy information.
